Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe

Euro Surveill. 2017 Feb 16;22(7):30464. doi: 10.2807/1560-7917.ES.2017.22.7.30464.

Abstract

We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0-14, 15-64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65-79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).

Keywords: ILI; SARI; immunisation; influenza; influenza like illness; severe acute respiratory infection; vaccine effectiveness; vaccines.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Europe / epidemiology
  • European Union
  • Female
  • Hospitals
  • Humans
  • Infant
  • Infant, Newborn
  • Influenza A Virus, H3N2 Subtype / immunology*
  • Influenza A Virus, H3N2 Subtype / isolation & purification
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / immunology*
  • Influenza, Human / epidemiology
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Middle Aged
  • Outcome Assessment, Health Care
  • Pandemics / prevention & control*
  • Population Surveillance
  • Primary Health Care
  • Seasons
  • Sensitivity and Specificity
  • Sentinel Surveillance
  • Vaccination / statistics & numerical data
  • Young Adult

Substances

  • Influenza Vaccines